Clene enters $7.3M subaward with Columbia University for NIH-funded ALS Expanded Access Program

Clene Inc.

Clene Nanomedicine signed subaward for up to $7.3M for initial phase of NIH grant supporting CNM-Au8 EAP in ALS.
Total subaward potential under $45.1M NIH grant could reach $30.9M through August 2027.
Funds reimburse expenses from Sept 25, 2023 to Aug 31, 2024; invoiced monthly or quarterly.
Agreement protects Clene's background IP; no license granted to Columbia or US Government.
Either party may terminate with 30 days' notice; termination required if NIH terminates grant.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Clene Inc. entered into Subaward with Colombia University valued at up to $7.3 million (effective 2024-04-03).

Action: entry
Counterparty: Colombia University
Value: up to $7.3 million
Effective: 2024-04-03

Exact text from the filing

On April 3, 2024, the Company entered into a grant subaward agreement (the “Subaward”) with Colombia pursuant to the NIH Grant.

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-011545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.